Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago
Amgen
University of Maryland, Baltimore
BioNTech SE
NRG Oncology
Sichuan University
Mayo Clinic
Swiss Cancer Institute
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Fox Chase Cancer Center
EpicentRx, Inc.
BeiGene
NantCell, Inc.
Sichuan University
EpicentRx, Inc.
Sichuan University
Nanfang Hospital, Southern Medical University
University of Washington
Canadian Cancer Trials Group
University of Washington
Alliance for Clinical Trials in Oncology
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Sun Yat-sen University
Wake Forest University Health Sciences
RTOG Foundation, Inc.
UNICANCER
UNICANCER
Fuzhou General Hospital
Abramson Cancer Center at Penn Medicine
Zhejiang Cancer Hospital
Radiation Therapy Oncology Group
Milton S. Hershey Medical Center
SWOG Cancer Research Network
University of California, Davis
Radiation Therapy Oncology Group
Sichuan Cancer Hospital and Research Institute
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Massachusetts General Hospital
Radiation Therapy Oncology Group
Northwestern University
New Mexico Cancer Research Alliance